Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

  • Technology appraisal guidance
  • TA377
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence